Labcorp Holdings Inc. (LH) is a Healthcare stock trading at $323.94 (as of 2026-09-15), with a market capitalization of $26.27B and a trailing P/E of 26.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Labcorp Holdings, Inc. provides laboratory services to support decision-making for doctors, hospitals, pharmaceutical companies, researchers, and patients. The company was founded on April 16, 2024 and is headquartered in Burlington, North Carolina.
Understand Labcorp Holdings Inc.: how it makes money
Labcorp runs clinical and biopharma laboratories, selling diagnostic tests to hospitals, physicians, and pharma clients on a volume basis. About 75% of revenue is routine diagnostics where pricing is payer-set, while the biopharma and specialty mix is where growth and margin upside live.
High-volume routine panels keep labs utilised at thin margins; the profit engine is the incremental mix shift into specialty and biopharma tests that carry structurally higher pricing and less payer-constraint.
Revenue by segment (latest quarter)
Diagnostics
$2.8B
Biopharma
$0.8B
Business quality (Mixed): Essential, recession-resistant demand and a growing specialty mix support the base case, but a 12% operating margin and heavy payer dependence cap the multiple versus higher-grading healthcare names.
Valuation: At 25× earnings, LH trades in line with the Healthcare Services average (25×).
Bull case
BLS backlog locks in growth: Management reported a BLS backlog of $8.7 billion, with $2.7 billion expected to convert into revenue within 12 months. That pipeline gives the biopharma segment (currently $780M per quarter) unusual multi-quarter visibility that most diagnostics peers lack.
Outgrowing the diagnostic market: Diagnostics volume grew 3% in the quarter, above management's 1% to 2% estimate for total market growth. Outpacing the high end of that range implies share gain from smaller or regional labs, which compounds the revenue base quarter over quarter.
Specialty mix lifts economics: Specialty testing delivered double-digit first-half growth across priority areas, pulling revenue toward higher-price, less payer-constrained assays. That mix trend is the clearest structural path to expanding the 12% operating margin over time.
Bear case
ACA change nibbles core volume: ACA-related policy changes reduced second-quarter diagnostic volume by approximately 20 to 30 basis points, a small but directionally meaningful signal that patient-access shifts are already trimming the routine base. If the drag persists, the 3% volume gain compresses toward the high end of the 1% to 2% market range, erasing the share-gain narrative.
Capex cycle squeezes cash flow: Free cash flow declined in the quarter due to working-capital timing and higher planned capital expenditures. Higher capex supports future capacity, but cash generation now lags the top-line story, a consideration when the stock trades at 24.7x earnings, roughly in line with the 25x industry average.
PAMA clouds reimbursement timing: Management flagged that PAMA implementation remains uncertain and potential further delays are under consideration. A delay preserves the current reimbursement methodology short term but defers a structural repricing of payer-billed tests, creating a binary overhang on the margin trajectory for a stock where 46.5% of Diagnostics revenue is third-party payer.